1 Title:

- 2 Rapid and modular workflows for same-day sequencing-based detection of bloodstream
- 3 infections and antimicrobial resistance determinants

4 Authors:

- 5 Mohammad Saiful Islam Sajib¹, Katarina Oravcova¹, Kirstyn Brunker^{1,2}, Paul Everest¹, Manuel
- 6 Fuentes¹, Catherine Wilson³, Michael E. Murphy^{3,4}, Taya Forde¹

7 Affiliations:

- 8 ¹ School of Biodiversity, One Health & Veterinary Medicine, University of Glasgow, Glasgow,
- 9 United Kingdom
- 10 MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
- 11 ³ Department of Microbiology, NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, New
- 12 Lister Building, Alexandra Parade, Glasgow, UK
- 13 ⁴ 13 Aschool of Medicine, Dentistry & Nursing, College of Medical, Veterinary & Life Sciences,
- 14 Wolfson Medical School Building, University of Glasgow, Glasgow, UK

15 Keywords:

- 16 rapid diagnosis, selective host depletion, chemical host depletion, metagenomic next
- 17 generation sequencing, Oxford Nanopore technologies, selective sequencing, adaptive
- 18 sampling, bloodstream infection, antimicrobial resistance
- 19
-

20

- 21
- 22
- 23
-
- 24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract:

27 Background: Bloodstream infections (BSI) are a major global health concern, and existing 28 diagnostic methods are too slow to guide targeted antibiotic therapy for critically ill patients, risking poor clinical outcomes. Rapid metagenomic-sequencing (mNGS) can facilitate swift pathogen and antimicrobial resistance (AMR) detection, but identification is challenged by significant host versus bacterial DNA in blood. To accelerate microbiological diagnosis, we developed M-15, a rapid and modular mNGS-based host DNA depletion workflow, validated with suspected BSI blood-culture samples and rapid culture-enriched spiked blood.

 Methods: To assess chemical host DNA depletion (CHDD) efficiency, M-15 was benchmarked with five commercial/published protocols. Later, M-15 was combined with rapid mNGS with/without adaptive sampling (AS) and tested on clinical blood-culture samples (n=33) from suspected BSI cases identified on BACT/ALERT VIRTUO (30 flagged positive, three remained negative). To determine whether it is possible to utilise M-15 mNGS prior to blood-culture flagging positive, a rapid enrichment method was tested starting with 1-10 colony forming units of the top 15 bacterial species causing BSI spiked into BACTEC medium enriched with 10 mL sheep blood.

42 Results: All six chemical depletion protocols reduced host DNA by $2.5x10^0$ to $4.1x10^6$ -fold, 43 with the in-house M-15 protocol performing best, while adaptive sampling depleted host >5- fold. With BACT/ALERT specimens, M-15 mNGS accurately identified 3/3 negative, 28/28 mono-bacterial, and 2/4 multi-bacterial species. With rapid culture-enrichment and M-15 mNGS, <18% DNA was classified as host and all bacterial species tested (n=10) were correctly identified. M-15 mNGS accurately predicted phenotypic AMR/susceptibility for 90.3% (232/257) of drug/bacteria combinations from BACT/ALERT positive samples.

49 Conclusions: This study demonstrates that M-15 mNGS can facilitate species and AMR gene detection within 5-7 hours of BACT/ALERT positivity. Including 8-hour culture enrichment, microbiological and AMR confirmation is possible within 13-15 hours of sample collection. Thus, the M-15 mNGS workflow has the potential to improve patient outcomes in BSI.

54 Background

55 Bloodstream infection (BSI) is one of the leading causes of death worldwide, with 2.9 million 56 cases each year [1]. Rapid identification of the causative bacterial pathogens and their 57 antimicrobial resistance (AMR) profiles is crucial for guiding more effective treatment and 58 better patient outcomes, especially for critically ill patients such as those who develop sepsis 59 [2]. Blood culture, the gold standard diagnostic method, often takes 48-72 hours, which is too 60 slow to guide targeted antibiotic therapy. This necessitates the prescription of empirical 61 antibiotics, which may fail to cover the resistance profile of the causative pathogen and risk 62 poor clinical outcomes [3]. Also, the use of broad-spectrum antibiotics to limit disease 63 progression may disrupt beneficial gut microbiota and contribute to the development of 64 multidrug-resistant bacteria often associated with healthcare infections, further limiting the 65 reserve of critically important antimicrobial agents [4]. Thus, there is an urgent need for rapid 66 diagnostic tools to better inform antibiotic regimens at the early stages of BSI. 67 Certain applications of metagenomic next-generation sequencing (mNGS) could be used to 68 rapidly identify bacterial species and AMR determinants, and therefore have the potential to 69 accelerate BSI diagnosis [5]. However, the proportion of host DNA in blood compared to that 70 of bacteria makes it challenging to directly sequence and generate adequate reads from the 71 pathogen to accurately identify species and AMR in a cost-effective manner and within a 72 clinically relevant timeframe. To address this issue, we developed a rapid mNGS-based 73 chemical host DNA depletion (CHDD) protocol, named M-15, and compared its performance 74 with two commercial kits (C1-2) and three published methods (P1-3) [6-8]. Next, M-15 mNGS 75 was validated with and without nanopore adaptive sampling using both culture (BACT/ALERT 76 an automated blood culture system) positive and negative enriched blood samples collected 77 from patients with suspected BSI. Finally, M-15 was combined and tested with a rapid (8-

- 78 hour) culture (BACT/ALERT) enrichment step to reduce turnaround time and enable same-day
- 79 microbiological diagnosis of bloodstream infections.

80 Methods

81 Bacterial strains and host matrix

82 Defibrinated sheep blood (E&O Laboratories, UK) and EDTA-treated whole blood from healthy 83 human volunteers were used as model host environment matrix. The list of clinical and/or

84 American Type Culture Collection (ATCC) strains tested/used in this study can be found in Tab.

85 1, S1, S2 and S3.

86 Primers, probes, and amplification parameters

87 To assess the depletion efficiency of the protocols, universal 16S rRNA, 18S rRNA and

88 bacterial species-specific primers and probes were utilised [9-12]. The total volume of

89 individual qPCR reactions was 20 µL, with 2x Rotor-Gene Multiplex PCR master mix (Qiagen,

90 Hilden, Germany) and 2 µL DNA template. $qPCR$ reactions were performed on a Rotor-Gene Q

91 real-time cycler for up to 40 cycles (Qiagen, Hilden, Germany). The primer/probe sequences,

92 concentrations and PCR cycling parameters are provided in Tab. S4.

93 Benchmarking host depletion kits and protocols

94 A chemical host DNA depletion protocol, named M-15, was developed in this study (Fig. 1,

95 Supplement Protocol: M-15 mNGS) and benchmarked alongside two commercial [Zymo-

96 HostZERO (named C1; Zymo Research, CA, USA), MolYsis-Complete5 (C2; Molzym GmbH &

97 Co, Bremen, Germany)] and three published host depletion protocols P1 [6], P2 [8], and P3

98 [7].

99 To determine host depletion efficiency and analytical sensitivity of the workflows, serially 100 diluted (100 to 105 CFU/mL) exponential growth phase cells of Escherichia coli (ATCC 25922), 101 Staphylococcus aureus (ATCC 25923), and Pseudomonas aeruginosa (ATCC 27853) strains 102 were spiked in 400 µL sterile whole blood (human and sheep) and processed to deplete host 103 cells/DNA with all the six protocols. Following host depletion with P1, P2, P3 and M-15, DNA 104 extraction was performed using QIAamp UCP Pathogen Mini Kit (Qiagen, Hilden, Germany) 105 with the recommended homogenisation step by bead beating (Pathogen Lysis Tubes L, 106 Qiagen, Hilden, Germany). For protocols C1 and C2, DNA extraction was performed using the 107 reagents supplied with the kits. Total DNA was extracted from the same spiked blood samples 108 without host depletion similarly as unenriched (non-CHDD) controls. Extracted DNA was 109 tested using qPCR with the 16S rRNA, 18S rRNA, and species-specific primers/probes 110 described above.

111 In addition, a subset of the simulated M-15 CHDD samples, containing 10^4 to 10^1 CFU/mL 112 blood was extracted, amplified and barcoded for sequencing using ONT Rapid PCR barcoding

- 113 kit (SQK-RPB004; Oxford Nanopore technologies, Oxford, UK) and sequenced on MinION
- 114 R9.4.1 flow cells. Live GPU basecalling was performed in high accuracy mode
- 115 (dna r9.4.1 450bps hac) and passed Fastq reads were analysed using Chan Zuckerberg
- 116 infectious diseases (CZ ID) (v0.7; https://czid.org/) Nanopore workflow (last accessed:
- 117 07/08/2024) [13].

118

119 Fig. 1: Schematic diagram depicting major steps involved in M-15 CHDD and mNGS workflow. Both 120 BACTEC flagged positive and rapid enriched (8-hour), blood culture samples can be used as input. M-121 15 CHDD is the first step where host DNA is selectively depleted with saponin and DNase I treatment. 122 Host depleted materal is then subjected to alkaline lysis and whole genome amplification with REPLI-g 123 single cell kit. Amplified product is then debranced using T7 Endonuclease I and sequencing is 124 performed with rapid barcoding (mid-low yield) or native barcoding (high-yield) kit.

125 Determining the contribution of host depletion on bacterial cell loss/viability

- 126 Bacterial cell loss and/or viability following host depletion was determined using *E. coli, S.*
- 127 *aureus,* and *P. aeruginosa* ATCC strains. Approximately 30 and 3 CFU of the exponential phase
- 128 cells were spiked in 400 µL sterile whole blood, and the samples were processed to deplete
- 129 host DNA with three top performing protocols C1, C2, P1, and M-15. Host depleted samples
- 130 were resuspended in PBS and plated on nutrient and blood agar media to estimate bacterial
- 131 concentrations using the method described by Miles & Misra [14]. The same samples were

132 plated directly without host depletion as controls. All the inoculated plates were incubated

133 overnight at 37°C, and the number of visible colonies was recorded the next day.

134 Rapid M-15 mNGS workflow tested on culture enriched specimens

135 To determine the efficiency of M-15 mNGS protocol on culture enriched samples, six culture 136 enriched suspected BSI samples were tested initially. Three samples flagged positive on 137 BACT/ALERT (bioMérieux, Marcy-l'Étoile, France) and the remaining three were reported to 138 be culture negative. The same samples were processed directly without M-15 as no depletion 139 controls. To minimise hands on time, rapid alkaline cell lysis was performed using 4 µL direct 140 or host depleted samples resuspended in 1 mL PBS using REPLI-g single cell kit (Qiagen, 141 Hilden, Germany). Multiple displacement amplification (MDA) was performed with the same 142 kit for 60 minutes according to the manufacturer's recommendation. Amplified MDA 143 products were then debranched for 10 minutes at 37° C using T7 endonuclease (New England 144 Biolabs, MA, United States) and subjected to 0.5x AMPure bead cleanup. Library was 145 prepared using ONT Rapid barcoding kit (SQK-RBK004) with 400 ng amplified debranched 146 DNA product/sample as an input (Supplement Protocol: M-15 mNGS + low-medium yield 147 protocol). The overall sample processing time of this pilot version of the workflow is 148 approximately 4 hours (processing 6-10 samples), including 80 minutes for host depletion, 20 149 minutes for DNA extraction (alkaline lysis method), 60 minutes of WGA using REPLI-g Single 150 Cell Kit, and 90 minutes for debranching, cleanup, library preparation and flow cell loading.

151 To assess the efficiency of adaptive sampling (AS) with or without CHDD with M-15, rapid

152 adapter ligated pooled libraries (six CHDD and six no CHDD) were loaded on a MinION R9.4.1

153 flow cell and the total number of channels (N= 512) available for sequencing were divided

154 into two parts from the advanced option menu on the MinKNOW graphical user interface.

155 Channels 1 to 256 were chosen for human DNA depletion using T2T-CHM13v2.0 as reference

156 [15] and channels 257-512 for no-adaptive sampling control.

157 High yield M-15 mNGS workflow validated with culture-positive suspected BSI specimens

158 An additional 27 blood culture positive samples were tested using the optimised workflow for 159 improved sequencing yield. Chemical host depletion, DNA extraction, MDA (60 minutes) and 160 debranching were performed similarly to the pilot protocol. Only this time, library preparation 161 was performed using Ligation Sequencing Kit (SQK-LSK109) with native barcodes (EXP-

162 NBD104) with 400 ng amplified debranched DNA product/sample as an input (Supplement 163 Protocol: M-15 mNGS + high yield protocol). The overall sample processing time of this 164 optimised workflow takes less than 6 hours (with 6-10 samples) including 80 minutes of 165 CHDD, 20 minutes for DNA extraction (alkaline lysis method), 60 minutes of WGA using REPLI-166 g Single Cell Kit, and about 180 minutes for debranching, library preparation and loading. 167 To identify bacterial species, CZ ID pipeline was utilised as mentioned above with a 20% 168 abundance cutoff (200,000 Base Per Million; BPM for CZ ID). Host-filtered contigs remaining 169 after the 20% abundance cutoff were analysed to identify AMR determinants with ResFinder 170 4.5.0 [16] using the default options. In addition, host filtered fastq reads remaining after 20% 171 abundance cutoff were mapped against bacterial reference sequences using minimap2[17] to 172 estimate the breadth of coverage and sequencing depth. To determine the minimum 173 sequencing yield required to identify bacterial species and AMR determinants, 100 Mbp, 50 174 Mbp, 40 Mbp, 30 Mbp, 20 Mbp, and 10 Mbp raw fastq reads were randomly subsampled

175 using rasusa [18] and processed similarly with CZ ID and ResFinder.

176 Rapid culture enrichment to accelerate microbiological diagnosis

177 A shorter culture enrichment method was tested with 16 ATCC/clinical isolates representing 178 eight Gram negative and seven Gram positive bacterial species. Approximately 1-10 CFU of 179 actively growing (log phase) bacterial cells were spiked in BD BACTEC[™] Standard Blood 180 Culture media (Becton, Dickinson and Company, NJ, USA) supplemented with 10 mL sterile 181 whole blood (sheep), and then subjected to incubation. Culture bottles were taken out at 2-182 hour intervals over a span of 10 hours and subsequently plated on nutrient and blood agar 183 media using the Miles & Misra method.[14] All the plates were incubated at 37°C overnight 184 and the number of visible colonies was recorded the next day. One mL culture-enriched 185 samples were preserved at -80°C during each sampling session to be tested later. Finally, a 186 subset $(10/16)$ of the 8-hour culture-enriched samples (5 Gram-positive and 5 Gram-negative 187 species) were chosen and processed with the high yield M-15 mNGS protocol (Supplement 188 Protocol: M-15 mNGS + high yield protocol). Species, host: pathogen ratio, antimicrobial 189 resistance genes and minimum DNA yield per sample for identification were determined 190 using the same pipelines and cutoffs mentioned above.

192 Conventional tests for detecting species, AMR, and predicting AMR with sequencing

- 193 In the routine diagnostic microbiology laboratory, 5-10 mL EDTA treated blood samples
- 194 collected from suspected individuals were incubated in the BACT/ALERT system for up to 5
- 195 days. Samples that flagged positive were taken out and inoculated onto appropriate agars,
- 196 and organisms grown identified using MALDI-TOF mass spectrometry (Bruker Corporation,
- 197 MA, USA). Phenotypic antimicrobial sensitivity was determined using disc diffusion as
- 198 described by European Committee on Antimicrobial Susceptibility Testing (EUCAST) guideline
- 199 [19] or automated systems, e.g. Vitek2 (bioMérieux, Marcy-l'Étoile, France).
- 200 To compare routine phenotypic sensitivity and genotypic antimicrobial susceptibility results,
- 201 AST results for the BACT/ALERT positive BSI samples were compared to ResFinder 4.5.0
- 202 phenotype table results. Because ResFinder provides AMR predictions for 92 antimicrobial
- 203 agents from 21 antibiotic classes, but only predicts resistance or susceptibility (not
- 204 Intermediate results), only the phenotypic results common between the two (culture and
- 205 sequencing) and classified as resistant or susceptible were compared. For rapid culture
- 206 enriched spiked blood samples, for which AST results were not available, WGS (where
- 207 available) and M-15 mNGS data of the ten ATCC/clinical isolates were compared similarly
- 208 using ResFinder 4.5.0 phenotype table. Categorical agreement, major error and very major 209 error were calculated using the following formula [20]:
- 210 Categorical agreement $=$ $\frac{TR + TS}{TR + TS + FR + FS}$
- 211

Major error ⁼ FR FR ⁺ TS ²¹²

213

$$
214 \t\t\t\tVery major error = \frac{FS}{FS + TR}
$$

- 215 Where: TR = True resistant, TS = True susceptible, FR = False resistant, FS = False susceptible,
- 216 and where phenotypic AST is taken as the gold standard.
- 217

219 Statistical analysis

- 220 R studio 2023.12.1 with R base version 4.3.3 were used in combination with readxl, dplyr,
- 221 reshape2, ggplot2, and gridExtra packages for performing data cleanup, formatting, analysis
- 222 and generating graphs.
- 223 Results

224 Chemical depletion protocols remove unwanted host with high efficiency

- 225 Protocols M-15 and P1 removed 4.1×10⁶ (Quantification cycle ΔCt-20.52) and 5.5×10⁵ fold (ΔCt-17.45)
- 226 host DNA, respectively, from the whole blood samples spiked with Escherichia coli, Staphylococcus
- 227 aureus, or Pseudomonas aeruginosa ATCC strains, with depletion efficiency over 99.99%. Commercial
- 228 kit C1 removed 99.82% (5.87×10² fold) host, and C2, 97.93% (4.84×10¹ fold). Approximately 81.09%
- 229 and 59.19% host were removed with the protocols P2 and P3, respectively (Tab. 1). Between 5.58%
- 230 (P3) and 51.63% (M-15) bacterial DNA were removed during host depletion with the six
- 231 kits/protocols. Protocols with higher depletion efficiencies also exhibited increased bacterial

232 DNA loss (Tab. 1).

- **233** Protocol C2 exhibited a strong negative bias towards *P. aeruginosa*, as >99% (ΔCt -10.27) loss
- 234 was observed, possibly due to the detrimental effect of buffer CM (a selective host cell lysis
- 235 buffer provided in the kit) on this bacterial species during the host lysis steps. In a recent
- 236 study, where blood culture positive samples were processed with protocol C2 to deplete host
- 237 and enable rapid sequencing-based species and AMR identification [20] sequencing results
- 238 also indicated suboptimal accuracy of C2 mNGS for *P. aeruginosa* compared to other bacterial
- 239 species, possibly indicating similar lysis bias [20].

240 Tab. 1: Host depletion efficiency and bacterial DNA loss observed with in-house chemical host DNA

241 depletion method, M-15, compared with two commercial kits (C1-2) and 3 published protocols (P1-3).

242 SD: Standard deviation, Ct: Cycle threshold, ΔCt: Difference in quantification cycle

243 CHDD protocols perform poorly with samples containing low bacterial concentrations

244 Although the host depletion efficiency of some of the protocols, including M-15 was

245 encouraging, we observed some bacterial loss. Therefore, we aimed to evaluate their

246 applicability on blood samples with low bacterial concentrations (1 to 100 CFU/mL), as 247 typically seen in BSI cases [21]. For this, we selected the top performing protocols, M-15, P1, 248 C1 and C2, which exhibited the highest host depletion efficiency. For all three ATCC strains 249 tested (*E. coli, S. aureus, P. aeruginosa*), gPCR analytical sensitivity of protocols M-15, P1 and 250 C1 was 10² CFU/mL. With protocol C2, qPCR was able to detect up to 10¹ CFU/mL *E. coli* and 251 *S. aureus*; however, like before, Ct values from *P. aeruginosa* spiked CHDD samples were 252 consistently very high (Ct >30) across all five *P. aeruginosa* concentrations (10⁰ to 10⁴ CFU/mL) 253 spiked in whole blood (Fig. 2A).

254 To understand which part (chemical wash or DNA extraction) of the CHDD protocols is 255 contributing to reduced recovery of bacterial DNA, we processed low abundant spiked samples 256 (<30 and <3 CFU/mL) with M-15, P1, C1 and C2 protocols and confirmed viability/recovery with 257 culture. Viable plate counts following CHDD showed protocols C1 retained 92%, M-15 76% and 258 P1 62% of bacteria of the low initial counts of <30 cells spiked in blood (Fig. 2B). With even 259 lower concentration (<3 cells), the overall bacterial recovery rate with protocols C1, M-15, and 260 P1 were 72%, 43% and 13% respectively compared to the no CHDD controls (Fig. 2B). No viable 261 bacteria were recovered using protocol C2 for any of the bacterial species or samples tested; 262 again, possibly indicating buffer CM's effect on their growth or viability, although *P. aeruginosa* 263 was the only species (specifically ATCC 27853) tested in this study that displayed suboptimal 264 performance with downstream molecular assays (Fig. 2B).

265 In order to estimate the proportions of expected bacterial DNA (i.e., bacterial species spiked 266 initially) versus host and others (unclassified and other species), a subset of simulated M-15 267 CHDD samples (highest host depletion efficiency; 4.1×10⁶ fold), having 10⁴ to 10¹ E. coli CFU/mL 268 were sequenced. While the host: bacteria DNA ratio might differ between bacterial species 269 due to the difference in their genome size, this would facilitate estimating the lowest bacterial 270 concentration (CFU/mL) that would most likely provide consistent results with downstream 271 molecular applications, especially sequencing. The proportion of expected bacterial (*E. coli* that 272 were initially spiked) DNA sequence yield (mega base pairs; Mbp) in M-15 CHDD samples were 273 -53.4% and 9.7% of total DNA for samples containing 10^4 and 10^3 CFU/mL bacteria respectively. 274 For low abundant samples, bacteria represented only 1.1% (10² CFU/mL) and 0.2% (10¹ 275 CFU/mL) of total DNA yield following >99.99% host removal with M-15 (Fig. 2C). Proportion of 276 DNA sequence yield from expected bacterial species compared to the host remained

277 unchanged throughout the sequencing run regardless of bacterial concentration spiked or DNA 278 ratio (Fig. 2C). The suboptimal host: pathogen ratio in low abundant blood samples meant that 279 sequencing-based assays may not yet provide satisfactory results even with CHDD, unless an 280 additional enrichment/depletion step is included pre/post DNA extraction to further improve 281 bacterial proportions, and a more robust and sensitive DNA extraction method is benchmarked 282 and validated.

283

284 Fig. 2: Overall performance of M-15 versus published/commercial protocols (A) qPCR Ct values 285 (median and standard deviation) of different concentrations (10^4 to 10^0 CFU/mL – see legend) of 286 three ATCC strains (*Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus*) spiked in 287 whole blood and processed with top chemical host DNA depletion (CHDD) kits/protocols (P1, M-15, 288 C1, and, C2) performing the best in terms of host DNA depletion. (B) Number of viable cells recovered 289 from blood samples spiked with <30 and <3 CFU of the three ATCC strains following CHDD with P1, M-290 15, C1, and, C2, compared to the no CHDD/PBS control. (C) Proportion of expected bacteria initially 291 spiked in blood for M-15 CHDD, compared to host (sheep) DNA, other bacterial species (different from 292 the three species spiked), and unclassified reads, over 16 hours of MinION sequencing. The four facets 293 are showing simulated/spiked bacterial concentration ranging from 10^4 to 10^1 CFU/mL of sheep blood.

294 M-15 mNGS and adaptive sampling significantly improve bacterial proportions

- 295 Due to suboptimal performance of M-15 mNGS observed with low bacterial concentrations
- 296 directly in blood samples, three BACT/ALERT positive (BCP01-BCP03) and three negative

297 (BCN01-BCN03) culture enriched samples from suspected BSI cases were initially tested with 298 a rapid version of M-15 CHDD protocol (Fig. 1).

 Length of the sequencing reads varied significantly among organisms, with expected bacterial 300 species (species that were identified with culture-based methods) having the highest median read length (1,957 bp); this was 8.15x longer than the unclassified reads (240 bp), 3.52x longer than human reads (552 bp) and 1.7x longer than other bacterial reads (mixed bacterial species not expected from the sample; 1,145 bp) (Fig. 3A). The read length difference between host and bacteria could be the result of CHDD, as host DNA was digested with 305 DNase I following selective lysis.

- 306 Overall yield in the adaptive sampling (AS) channels (1-256) was 1.86x lower (550.33 Mbp AS
- 307 vs 1023.72 Mbp no-AS) than no-AS (channels 257-512), although the total number of reads
- 308 for AS and no-AS samples was almost the same, with 345,085 and 334,054 reads,
- 309 respectively. Median read length for AS channels was 3.2x shorter than the no-AS, and host
- 310 constituted >90% of the reads that were smaller than 1kb in AS channels (Fig. 3B). This
- 311 illustrates that AS influenced the length of sequenced fragments as a result of its limited
- 312 ability to deplete shorter host reads (\leq 1 Kbp), which were highly abundant in the directly
- 313 extracted no-CHDD samples.

314 Samples processed with M-15 CHDD had 1.14×10^3 times less human DNA compared to the

315 no CHDD controls (based on sequencing yield in Mbp; Fig. 3D). Samples sequenced using AS

316 had 5.52-fold less human DNA compared to the controls; however, no bacterial enrichment

- 317 was observed (Fig. 3C, 3D). This highlights the importance of host depletion even in positively
- 318 flagged culture-enriched specimens, as it may lead to lower sequencing cost per sample, and
- 319 more importantly, reduce the sequencing time required to reach a desired yield for
- 320 determining the bacterial species responsible for the BSI.

It is made available under a CC-BY-NC-ND 4.0 International license.

321

322 Fig. 3: Host depletion efficiency of M-15 mNGS and adaptive sampling (AS), versus no chemical 323 host DNA depletion (CHDD) and no AS, tested with patient samples (A) Violin plot showing size 324 distribution of sequencing reads aligned to expected bacterial species, host (human), other bacterial 325 species, and reads for which there were no matches within the blast Nr/Nt database. (B) Histogram 326 highlighting the number of raw sequencings reads from expected bacteria, host, others (other 327 bacteria or unclassified). Coloured facets subdividing the raw reads further to distinguish read length 328 variation by AS, no AS and CHDD and no CHDD. (C) Overall sequencing yield of CHDD and no-CHDD 329 samples sequenced, comparing AS and no-AS. Stacked coloured bars highlight the proportion of DNA 330 aligned to host, bacteria and others/unclassified species (see legend). Blood culture positive (BCP) 331 samples are shown in red text, while blood culture negative (BCN) samples are shown in black. (D) 332 Depletion efficiency (fold difference, FD) in DNA yield (Mbp) of sequences from host with CHDD and 333 AS compared to no-CHDD and no-AS.

334 M-15 mNGS accurately predicts mono-bacterial species in BACT/ALERT positive samples

335 Because suboptimal sequencing yield was observed when debranched M-15 CHDD Multiple 336 Displacement Amplification (MDA) samples were initially processed (rapid M-15) using the 337 rapid barcoding kit $(Fig. 1)$, it was decided to utilise the Ligation sequencing kit with native

338 barcodes (Fig. 1). Additional 27 culture (BACT/ALERT) positive BSI blood samples were 339 processed with the high-yield M-15 mNGS protocol.

340 Overall, blood-culture positive (BCP) samples subjected to CHDD had 152.4x higher DNA 341 concentration compared to culture negative (BCN) samples (BCP CHDD 509.02 ng/ μ L versus 342 BCN CHDD 3.34 ng/ μ L, as measured using Qubit) after 60 minutes MDA (Fig. 4A, Tab. S1). 343 However, directly extracted and amplified blood culture negative samples yielded 753 ng/ μ L 344 DNA on average following 1-hour MDA with REPLI-g kit (Tab. S1). Four bacterial species with 345 high GC content, *Brevibacterium luteocum* (GC 67.8%)*, Micrococcus luteus* (GC 74.0%)*,* 346 *Stenotrophomonas maltophilia* (GC 66.7%) and *Achromobacter xylosoxidans* (GC 64.0%) 347 yielded low DNA (15.7x less than other species), with an average of 32.23 ng/ μ L after 1-hour 348 MDA; however, this was still 9.64x higher than BCN samples following CHDD (Tab. S1). The 349 potential reason behind low yield in species with high GC%could involve stable secondary 350 structure or denaturation difficulties as highlighted in some studies [22, 23]. 351 With CZ ID, using a cutoff of 20% abundance (200,000 Bases Per Million: BPM) successfully 352 removed all bacterial species identified except those detected using culture-based methods. 353 Using this cutoff, sequencing correctly identified 28/28 mono-bacterial species, 3/3 negative 354 samples and 2/4 multi-bacterial species found in two samples (Fig. 4B, S1 A). 355 Initially, it was assumed that the two species (*K. oxytoca* and *E. faecalis*) in two mixed samples 356 (BCP05, and BCP24) were missed due to bacterial cell lysis during CHDD (Fig. 4B). However, 357 some of the mono-bacterial samples tested in this study contained the same bacterial 358 genera/species and no negative bias was observed with sequencing following CHDD. Also, all 359 the CHDD flagged positive samples (n=30, species=17) were cultured overnight to confirm 360 viability, and only one (*M. luteus*) showed visible growth impairment on agar plates (Tab. S1). 361 Therefore, it is likely that these two organisms were missed with sequencing due to their 362 relatively low abundance compared to the other species present in the sample. For one 363 sample (BCP15), *Klebsiella pneumoniae* was iden<fied with culture but *Klebsiella variicola* 364 with mNGS; however, the species was later confirmed to be *K. variicola* with 16S rRNA 365 amplicon sequencing. Overall, expected bacterial species constituted 88.7% of total 366 sequencing yield versus human which represented only 0.46% total DNA (Fig. 4B).

369 Fig. 4: Species and antimicrobial resistance prediction accuracy of M-15 mNGS (A) DNA 370 concentration (ng/μL) of three blood culture negative (BCN01-BCN03) and 30 blood culture flagged 371 positive (BCP) samples, following M-15 chemical host DNA depletion (CHDD), and whole genome 372 amplification with the REPLI-g kit. Quantification was performed with Qubit Broad Range dsDNA assay. 373 (B) Proportion of expected bacterial DNA (yellow bar chart; confirmed by culture) versus all other 374 reads following M-15 CHDD and MinION sequencing with native barcoding kit. BACT/ALERT positive 375 samples that have species-level agreement with culture have text labelled dark blue, those with 376 genus-level agreement are purple, and those not detected by sequencing are labled red. (C) 377 Cumulative depth for eight Gram-positive and nine Gram-negative organisms from 30 BACT/ALERT 378 positive blood culture samples following M-15 mNGS, with 100 Mbp sequencing yield per sample. (D) 379 Number and proportion of true positive, true negative, false positive and false negative AMR 380 predictions with M-15 mNGS compared to the standard culture-based AST prediction for 30 381 BACT/ALERT positive blood culture samples. (E) Number and proportion of ResFinder true positive, 382 true negative, false positive and false negative AMR predictions with M-15 mNGS by bacterial species

383 from the 30 BACT/ALERT positive blood culture samples tested in this study. (F) Number and 384 proportion of true/false AMR predictions with mNGS for the same culture-positive samples 385 categorised by antibiotics tested. Prediction of AMR profile with mNGS was done only using the 386 resistance and susceptibility results from antibiotics that were present in both phenotypic and 387 genotypic datasets (n=257).

388 To understand the breadth of coverage across the bacterial genomes with 100 Mbp 389 sequencing yield per CHDD sample, 100 Mbp fastq reads subsampled with rasusa were 390 analysed. For every 100 Mbp DNA sequenced per sample, 96.76% and 99.48% coverage could 391 be achieved with at least $1x$ depth for the Gram-positive and Gram-negative organisms 392 tested, respectively. For 5x and 10x depth, Gram positive organisms had a mean genome 393 coverage of 87.89% and 78.29% and Gram-negatives 95.28% and 78.38%, respectively (Fig. 394 $4C$). For all the 30-blood culture positive samples tested (BCP01 to BCP30), >20% abundance 395 cutoff accurately identified the present bacterial species with as low as 10 Mbp sequencing 396 yield per sample (Fig. S1 A).

397 Rapid culture enrichment can facilitate same-day microbiological identification

398 When a blood culture is flagged as positive, it contains approximately 10^7 to 10^9 bacterial

399 cells/mL of culture broth [24], which is more than the input concentration ($\geq 10^4$ CFU/mL)

400 required for the M-15 mNGS to work reliably, as observed during our initial experiments (Fig.

401 2C). This meant that a shorter culture enrichment step could further accelerate the

402 microbiological diagnosis, and M-15 mNGS could be utilised even before a sample flags

403 positive. However, given the variety of bacterial species involved in BSI and differences in their

- 404 growth rate, we aimed to understand the minimum incubation period required to reach that
- 405 threshold with a representative range of clinically important bacterial species ($n=15$).
- 406 Four of 15 bacterial species tested (*Streptococcus agalactiae*, *Acinetobacter baumanii*,

407 Klebsiella pneumoniae and *Escherichia coli*) reached 10⁴ CFU/mL, the optimal concentration

408 for M-15 mNGS, under 6 hours of culture enrichment (Fig. 5A). With 8-hour incubation,

- 409 $12/15$ species reached the desired threshold of $10⁴$ CFU/mL. The remaining three species,
- 410 *Staphylococcus aureus, Streptococcus pneumoniae* and *Pseudomonas aeruginosa*, were
- 411 slightly lagging, reaching approximately $6.04x10^3$ CFU/mL on average with 8-hour enrichment.
- 412 All the species (15/15) tested reached/crossed the threshold under 10 hours of culture
- 413 enrichment (Fig. 5A).

414 To identify proportions of expected bacteria obtained using M-15 mNGS after 8-hour rapid 415 culture enrichment, three sterile blood culture samples and a subset of 10 bacterial species (5 416 Gram positive and 5 Gram negative, including the three slow-growing species tested earlier) 417 were selected and processed with this approach (Fig. 5A, C). One potential costly drawback 418 with the rapid enrichment approach could be the necessity to blindly sequence all blood 419 cultures if the positive and negative samples could not be differentiated prior to sequencing. 420 However, following CHDD and 60 minutes of MDA, the rapid culture-enriched spiked blood 421 samples (RESB, n=10) showed 28.16x higher dsDNA concentration (154.6 versus 5.49 ng/ μ L) 422 on average compared to sterile human blood enriched as negative controls (SBC, $n=3$), 423 providing a unique signature for the detection of positive samples prior to sequencing (Fig. 424 5B, Tab. S2). 425 Following sequencing, expected bacteria represented 89.4% of total DNA yield on average for

426 7 samples that reached 10⁴ CFU/mL under 8-hours versus 50.06% for the remaining 3

427 samples having relatively slow-growing species. All samples combined, 75.4% of the total DNA

428 yield matched with the bacterial species initially used for spiking and enrichment and 17.64%

429 with host species (Fig. 5C). Similar to BACT/ALERT positive samples, >20% abundance

430 threshold successfully identified 10/10 bacterial species sequenced to validate the rapid

431 enrichment protocol (Fig. 5C). Also, like before, as low as 10 Mbp yield (subsampled) was

432 sufficient to accurately identify bacterial species with the abovementioned cutoff (Fig. S1 B).

It is made available under a CC-BY-NC-ND 4.0 International license.

434 Fig. 5: Rapid culture enrichment: species covered, overall accuracy in species and antimicrobial

435 resistance prediction. (A) Time to reach 10^4 colony forming units (CFU)/mL (green line; optimal 436 concentration for chemical host DNA depletion (CHDD) with culture-based bacterial enrichment prior 437 to M-15 CHDD and mNGS, tested with the top 15 bacterial species causing bloodstream infection. (B) 438 DNA concentration (ng/μL) of the three strerile culture-enriched blood (SBC01-SBC03) and ten rapid 439 (8-hours) culture enriched spiked blood samples, following M-15 CHDD, and whole genome 440 amplification with the REPLI-g kit. Quantification was performed with Qubit broad range assay. (C) 441 Proportion of expected bacteria (yellow; spiked initially) versus all other reads following M-15 CHDD 442 and MinION sequencing. Species, genus and non-agreements from rapid culture-enriched samples are 443 highlighted with the same colored labels as before. (D) Number and proportion of ResFinder true

444 positive, true negative, false positive and false negative AMR predictions with M-15 mNGS compared

445 to the whole genome sequencing (WGS) results of the same isolates/strains. MR: methicillin-resistant

446 *In silico* prediction of AMR is promising but requires improvement for clinical use

- 447 The accuracy of AMR prediction for the BACT/ALERT positive samples was determined
- 448 comparing the ResFinder phenotype antibiotic data with the phenotypic culture-based
- 449 antimicrobial susceptibility testing (AST) results (n= 257). For all 30 culture positive samples,
- 450 mNGS exhibited 90.32% (232/257) categorical agreement overall, with 8.49% (18/212) major
- 451 error and 15.55% (7/45) very major error (Fig. 4D). Among the 17 bacterial species,

 discrepancies in resistance calls for *K. michiganensis* (5/18), *K. pneumoniae* (6/18), and *S. aureus* (5/18) contributed to the highest number of major errors, and *E. coli* (2/07) and *S. epidermidis* (2/07) towards very major error (Fig. 4E). Of 27 antibiotics for which results were compared, very major error for ciprofloxacin was most common (3/7), possibly due to the 456 relatively low accuracy of ONT reads and the frequent association of resistance to 457 fluoroquinolones with mutations in quinolone resistance determining region (QRDR) of DNA gyrase and topoisomerase encoding genes, as opposed to resistance encoding gene 459 presence/absence in other antibiotics.[25] Clindamycin (4/18) and piperacillin/tazobactam $(3/18)$ were the top two antibiotics exhibiting major errors (Fig. 4F).

461 Due to the smaller number of ATCC strains and clinical isolates ($n = 10$) tested, and

462 unavailability of phenotypic AST data for a few clinical isolates, AMR predictions of M-15

463 mNGS with the rapid culture method were compared to whole genome sequencing (WGS) of

464 pure bacterial strains predicted AMR of the same strains/species using ResFinder (n = 920

465 predictions). Overall categorical agreement for M-15 mNGS versus WGS was 98.7% (908/920)

466 and mNGS exhibited 89.1% true susceptible, 9.6% true resistant, 1.3% false susceptible and

467 no false resistant predictions (Fig. 5D). *P. aeruginosa* was the only species for which

468 sequencing results did not match perfectly with its reference genome (12/92 predictions) and

469 therefore was the only source of false susceptibility, possibly due to its high GC content

470 leading to inefficient/uneven DNA amplification with the REPLI-g kit (Tab. S2).

471 For both BACT/ALERT positive blood culture and rapid enriched spiked blood M-15 CHDD

472 blood, ≥50 Mbp sequencing yield was sufficient to predict AST profiles, with the accuracy

473 almost the same as having a sequencing yield of >100 Mbp per sample (Fig. S2, S3).

474 Discussion

475 Timely identification of pathogens and their antimicrobial resistance profile is crucial in BSI 476 because more targeted and effective antibiotic therapy can minimise the progression and 477 severity of the disease and therefore lead to improved patient outcomes. In addition, 478 reduced prescription of broad-spectrum antibiotics may help preserve their effectiveness, 479 limit the emergence of new antibiotic-resistant strains and protect the valuable microbiota 480 that plays an important role in maintaining overall nutrition and health [26]. Rapid 481 sequencing-based methods, especially in combination with selective chemical depletion

 approaches, have the potential to reduce turnaround time and therefore lessen detrimental outcomes. In working towards this goal, this study initially assessed the effectiveness of five published and commercial, one in-house and one computation-based host depletion strategies.

486 As a first step, we compared the effectiveness of an in-house host depletion method (M-15) 487 with five published and commercial approaches, as well as a computation-based host 488 depletion strategy. The host depletion efficiency of most of the CHDD workflows was 489 outstanding (particularly for M-15 and P1). However, we also noticed a correlation between 490 depletion efficiency and loss of bacterial DNA with some protocols (e.g., C2) showing 491 significant negative bias towards some species. For samples with low bacterial abundance, 492 the proportion of bacterial DNA was insignificant, $\leq 1\%$ of total DNA, even after M-15 CHDD, 493 which can remove >99.99% host DNA. However, bacteria represented >50% of total DNA 494 sequence yield for the CHDD samples containing $\geq 10^4$ CFU/mL bacteria. This meant additional 495 enrichment/depletion was necessary to get improved proportions of the sequencing yield 496 that is bacterial. As a simple and cost-effective alternative, we realised that a culture-based 497 enrichment step prior to CHDD and sequencing might improve DNA extraction 498 efficiency/robustness and proportion of bacteria in the sample simultaneously.

499 Therefore, we initially tested BACT/ALERT positive samples with two versions of M-15 mNGS 500 protocols. As confirmed during the initial phase, the proportion of host: bacterial DNA 501 sequenced was improved significantly with CHDD and AS. However, the sequencing yield was 502 suboptimal when CHDD whole genome amplification (WGA) was paired directly with the 503 Rapid Barcoding Kit (not systematically tested). The best output was observed when 504 debranched MDA products were barcoded using the Ligation Sequencing Kit, although it 505 requires additional hands-on time and potentially pricier reagents for library preparation. 506 Both versions of the workflows have their own strengths and limitations; for example, the 507 rapid workflow requires less hands-on time but may result in relatively low sequencing yield, 508 leading to higher sequencing cost per sample (Fig. 1). In contrast, the high-yield workflow 509 would reduce sequencing cost by providing greater output with only 90 additional minutes 510 for sample processing (Fig. 1). Several studies have already highlighted this difference;[27, 28] 511 consequently, users may choose the workflow that best suits their need/budget.

512 Although there are multiple bioinformatic pipelines available for mNGS-based species 513 identification, only a few have been developed/standardised for diagnosing bloodstream 514 infection. The aim of this study was therefore not to benchmark these pipelines; instead, we 515 assessed the utility of one of the well-regarded workflows, CZ ID, in combination with M-15 516 mNGS. With the 20% (200,000 BPM) abundance cutoff, sequencing accurately identified 3/3 517 negative, 28/28 mono-bacterial and 2/4 multi-bacterial species reported in two samples, with 518 >88% DNA classified as the expected species. To determine minimum sequencing yield 519 required to accurately identify bacterial species, we randomly subsampled the reads under 520 the established assumption (Fig. 2C) that the proportion of host: bacteria remains consistent 521 throughout a sequencing run [29]. The results demonstrated that the species prediction 522 accuracy with the given cutoff remains nearly identical even with 10 Mbp yield per sample. 523 Therefore, it is not entirely necessary to generate hundreds of Mbp reads/sample to cover 524 \sim 200% of the genome with >20x depth for patient management unless the aim is to utilise 525 this data for hospital outbreak investigation.

526 With the rapid culture enrichment, only a few species tested reached/crossed $\geq 10^4$ CFU/mL 527 threshold under 6 hours, and at least 8 hours of incubation was required to get more 528 comprehensive representation of critically important Gram-positive (n=7) and Gram-negative 529 (n=8) bacterial pathogens. M-15 CHDD and sequencing of a subset of rapid (8-hour) enriched 530 samples (5 Gram-positive and 5 Gram-negative) further confirmed our hypothesis: sequence 531 reads from expected bacteria represented >75% of total yield, and similar to BACT/ALERT 532 positive samples, only 10 Mbp reads accurately identified species with the previously assigned 533 abundance threshold.

534 Regarding AMR prediction, it is worth highlighting that not all expected molecular 535 mechanisms of antibiotic resistance have been determined [30]. Additionally, a mere 536 presence or absence of genes and/or mutations does not always correlate to phenotypic 537 resistance or susceptibility [30]. Therefore, at present, it is less likely that a sequencing-based 538 approach would match culture-based phenotypic results with 100% accuracy for all the 539 bacterial species commonly identified in BSI. Like species identification, several workflows can 540 predict AMR using mNGS data. The underlying principles, databases and/or accuracy can vary 541 among these workflows for AMR identification [31]. Therefore, it was decided to test 542 ResFinder, a well-regarded workflow, with M-15 mNGS, as benchmarking several

543 workflows/bioinformatic pipelines was not within the scope of this study. M-15 mNGS 544 combined with ResFinder exhibited overall 90.3% accuracy 8.49% major and 15.55% very 545 major error with BACT/ALERT positive samples. These proportions closely match with some of 546 the other studies that utilised culture enriched samples for metagenomic sequencing, 547 although very major error rates with M-15 mNGS were found to be marginally lower [20]. 548 With rapid culture-enriched samples, WGS data was used as comparator. Although this is less 549 ideal than comparing with culture-based phenotypic results, we wanted to understand how 550 closely mNGS results matched those of reference sequences of bacteria that were used for 551 spiking. With 920 ResFinder AST predictions, mNGS showed 98.7% categorical agreement, 552 and only 1.3% false susceptibility, primarily due to *P. aeruginosa*, the only species exhibiting 553 discordant results. Similar suboptimal results with *P. aeruginosa* were also observed in the 554 aforementioned study [20]. However, in our case, this likely stemmed from inefficient/uneven 555 DNA amplification due to high GC content of *P. aeruginosa* (66.6%), as we did not observe any 556 lysis/viability issues with culture when CHDD samples were plated on agars (Tab. S2)*.*

557 Considering the overall performance, it seems more work is required in terms of wet/dry lab 558 to make AMR predictions more accurate (e.g., Q30 reads and/or utilizing machine learning 559 models [32]) to be accepted as a replacement of blood culture and phenotypic assays. 560 However, as an addition to existing methods, M-15 mNGS at its current stage still holds 561 promise to inform treatment in comparison to empirical antibiotic therapy. For clinical 562 management of BSI or infection in general, the accuracy of empirical treatment can range 563 from 20% to 80% [33-35]. This means that a high proportion of cases receive inappropriate 564 antibiotics until more targeted therapy is administered utilizing the phenotypic AST results 565 (conventionally available in 48-72 hours), potentially risking detrimental outcomes for 566 critically ill patients [34]. With the rapid availability of bacterial species and AMR predictions 567 that surpass empiric prescription and therapy, mNGS can significantly refine the choice of 568 antimicrobials, increasing the likelihood of favourable outcomes. That being said, thorough 569 clinical validation would be required for rapid M-15 mNGS to be recommended for clinical 570 implementation.

571 A possible costly drawback when implementing the rapid enrichment approach was the 572 necessity to blindly sequence all blood cultures if the culture positive and negative samples 573 could not be differentiated prior to sequencing. However, when compared to the negative

574 blood samples, both BACT/ALERT positive and rapid enriched spiked M-15 CHDD blood had 575 152x and 28x higher dsDNA concentration following MDA, meaning any negative samples 576 could potentially be filtered out prior to sequencing if their Qubit-measured DNA 577 concentration provides a differentiable signature, as we observed following CHDD and WGA 578 (Tab. S1, S2)*.* However, the exact cutoff must be determined site-wise (different clinical 579 settings or in different laboratories) with more negative patient samples before 580 implementation in a clinical setting. It is important to note that this differentiation is only 581 possible with rapid CHDD as direct extraction and amplification would not provide a 582 discernible characteristic for negative samples due to the overwhelming abundance of host 583 DNA masking the unique signature from the bacteria (Tab. S2). This approach may incorrectly 584 flag some slow growing and/or bacterial species with high GC% as negative. However, 585 because M-15 mNGS is currently intended to complement existing technologies rather than 586 replacing them, species that might be missed would still be captured with traditional culture-

587 based methods.

588 It is important to recognise that this study had several limitations. Since we only had access to 589 different volumes of surplus EDTA treated blood samples from the suspected BSI cases, stored 590 in a refrigerator for up to five days until reporting was complete, it was decided not to test the 591 rapid enrichment workflow on patient samples. Instead, 15 clinically important bacterial 592 species were chosen for initial validation. This is because the different volume and extended 593 storage of the samples might alter the host/pathogen ratio, affect viability, and/or change the 594 actual growth of the bacteria and therefore might not be an appropriate representative of 595 freshly drawn samples.

596 Also, the rapid and high yield mNGS workflows were benchmarked, and a few batches of 597 samples were initially processed using R9.4.1 flow cells, before more accurate R10.4.1 kits 598 became widely available on the market. Therefore, it was decided to continue testing all the 599 samples with library kits compatible with R9.4.1 flow cells [27]. We believe that the 600 performance of M-15 CHDD would be further enhanced with the use of newer versions of 601 kits/flow cells, as a higher proportion of \geq Q20 reads would likely allow mutations associated 602 with AMR to be more reliably predicted.

It is made available under a CC-BY-NC-ND 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.09.24315014;](https://doi.org/10.1101/2024.10.09.24315014) this version posted October 9, 2024. The copyright holder for this
preprint <mark>(which was not certified by peer review)</mark> is the author/funder, who has grant

604 Conclusions

630 Abbreviations

- 631 AMR: Antimicrobial resistance
- 632 AS: Adaptive sampling
- 633 AST: Antimicrobial susceptibility testing
- 634 ATCC: American Type Culture Collection
- 635 BSI: Bloodstream infection
- 636 BPM: Bases per million
- 637 CFU: Colony-forming units
- 638 CHDD: Chemical host DNA depletion
- 639 dsDNA: Double-stranded DNA
- 640 EUCAST: European Committee on Antimicrobial Susceptibility Testing
- 641 FDA: Food and Drug Administration (USA)
- 642 GC%: Guanine-cytosine content percentage
- 643 mNGS: Metagenomic next-generation sequencing
- 644 Mbp: Megabase pairs
- 645 MDA: Multiple displacement amplification
- 646 NHS: National Health Service (UK)
- 647 ONT: Oxford Nanopore Technologies
- 648 PBS: Phosphate-buffered saline
- 649 qPCR: Quantitative polymerase chain reaction
- 650 RBC: Red blood cells
- 651 WGA: Whole-genome amplification
- 652 WGS: Whole-genome sequencing

653 Funding

- 654 This study was funded by Royal Society Research Grant (RGS\R1\211163) and University of
- 655 Glasgow's Lord Kelvin Adam Smith (LKAS) Ph.D. studentship.

656 Ethical statement

- 657 This study was reviewed and approved by the University of Glasgow College of Medical,
- 658 Veterinary & Life Sciences Ethics Committee (Project No: 200210015) and UK National Health
- 659 Services (NHS) Greater Glasgow and Clyde (R&I reference: GN19ID331). No personal
- 660 information from the patients and healthy volunteers was collected and used in this study.
- 661 Human DNA reads obtained from mNGS were excluded or not utilised for any bioinformatics
- 662 analyses beyond quantifying the number of hosts reads generated.

663 Availability of data and materials

- 664 All the raw sequencing reads (fastq.gz: host excluded) analysed and presented in this study
- 665 are available on European Nucleotide Archive under the study accession "PRJEB80726".

666 Authors' contributions

667 Conceptualisation of this study was carried out by TF and MSIS. Data generation, cleaning, 668 management, formal analysis, and initial draft was written by MSIS. Project investigation, 669 experimental method selection, clinical sample collection, formal review and coordination 670 was done by TF, KB, KO, PE, MEM, CW, MF, and MSIS. TF (RS) and MSIS (LKAS) acquired 671 funding for this project.

672 Acknowledgements

673 We would like to thank Kareen Macleod for generously providing the reference isolates used 674 in this study. We also want to express our gratitude to Ryan Carter and Ângelo Mendes for 675 their help and input on this project.

676

677

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.09.24315014;](https://doi.org/10.1101/2024.10.09.24315014) this version posted October 9, 2024. The copyright holder for this
preprint <mark>(which was not certified by peer review)</mark> is the author/funder, who has grant

It is made available under a CC-BY-NC-ND 4.0 International license.

References

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.09.24315014;](https://doi.org/10.1101/2024.10.09.24315014) this version posted October 9, 2024. The copyright holder for this
preprint <mark>(which was not certified by peer review)</mark> is the author/funder, who has grant

It is made available under a CC-BY-NC-ND 4.0 International license.

It is made available under a CC-BY-NC-ND 4.0 International license.

801 Supplementary Figures, tables and protocols

802
803

Fig. S1: Accuracy of species prediction with varying sequencing yield (100 Mbp to 10 Mbp),

804 identified by subsampling the (A) reads from 17 bacterial species from the 30 BACT/ALERT positive 805 blood culture samples and (B) 10 rapid (8-hours) culture enriched spiked blood samples. Analysis was 806 performed similarly using CZ ID with the same abundance threshold for all the species tested. Colored 807 gradient highlights the species that passed the initial threshold filter and their abundance (base per 808 million) in the CHDD samples that were sequenced.

809
810

Fig. S2: Antibiotic susceptibility profiles predicted with varying sequencing yield (>100 Mbp to 10

811 Mbp/sample) using subsampled reads from the 30 BACT/ALERT positive blood culture samples. (A) 812 The heatmap is showing antimicrobial resistance profiles and (B) the barplot highlights the number of

813 antimicrobials from different antibiotic classes identified with different sequencing yield for

- 814 BACT/ALERT positive samples.
- 815
- 816
- 817
- 818
- 819
- 820
-
- 821

It is made available under a CC-BY-NC-ND 4.0 International license.

822

823 Fig. S3: Antibiotic susceptibility profiles predicted with varying sequencing yield (>50 Mbp to 10

824 Mbp/sample) using the subsampled reads from 10 rapid culture enriched (8-hours) spiked blood 825 samples. (A) The heatmap shows antimicrobial resistance profiles and (B) the barplot highlights the 826 number of antimicrobials from different antibiotic classes identified with different sequencing yield for 827 rapid culture enriched spiked blood samples.

- 828
- 829
- 830
- 831
- 832

It is made available under a CC-BY-NC-ND 4.0 International license.

833 Tab. S1: Double stranded DNA concentration of three BACT/ALERT negative (BCN01 to BCN03) and 30

834 BACT/ALERT positive blood culture (BCP) samples quntified by Qubit following M-15 CHDD and 60

835 minutes of multiple displacement amplification with REPLI-g kit. As controls, six samples (BCN01 to

836 BCN03 and BCP01 to BCP03) were also extracted directly and amplified similarly for 60 minutes

837 without CHDD. Viability of bacterial following M-15 CHDD was confirmed by plating the supernatant

838 on nutrient and blood agar media.

It is made available under a CC-BY-NC-ND 4.0 International license.

- 840 Tab. S2: Double stranded DNA concentration of three 8-hour culture enriched sterile blood (HB1 to
- 841 HB3) versus ten spiked blood (1-10 CFU) samples following 60 minutes of multiple displacement
- 842 amplification with REPLI-g kit with and without M-15 chemical host DNA depletion (CHDD) measured
- 843 by Qubit. Viability of bacteria following M-15 CHDD was confirmed by plating the supernatant on
- 844 nutrient and blood agars.

- 845
- 846
- 847
- 848
- 849
- 850
- 851
- 852
- 853
- 854
- 855
- 856
- 857
- 858
- 859
- 860
-
- 861

It is made available under a CC-BY-NC-ND 4.0 International license.

862 Tab. S3: AMR gene profile (genes expected based on whole genome sequencing data) of the 8-hour 863 culture-enriched blood samples chosen for sequencing (n=10). Following M-15 mNGS, sequencing

864 reads were analysed with ResFinder to match and confirm the presence/absence of the same AMR

865 determinants expected from the species initially utilised for spiking. Prediction accuracy of AMR

866 (Match%) was determined comparing the ResFinder predicted phenotypic AST results of M-15 mNGS

867 versus previously sequenced clinical/ATCC strains.

- 868
- 869

870

871

872

- 873
- 874
- 875

876

877

878

- 880 Tab. S4: Primer, probe sequences and their reaction concentrations used in this study for detecting
- 881 universal 16S (bacteria) and 18S Ribosomal ribonucleic acid-rRNA (host) genes and species-specific
- 882 genes to identify three bacterial species, (*Escherichia coli* (EC), *Pseudomonas aeruginosa* (PA), and
- 883 Staphylococcus aureus (SA)) used for initial spiking and benchmarking experiments.

884

885

886

887

888

889

890

891

892

893

894

895

896

897 898

It is made available under a CC-BY-NC-ND 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.09.24315014;](https://doi.org/10.1101/2024.10.09.24315014) this version posted October 9, 2024. The copyright holder for this
preprint <mark>(which was not certified by peer review)</mark> is the author/funder, who has grant

900 Supplement Protocol: M-15 mNGS

901 Consumables

It is made available under a CC-BY-NC-ND 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.09.24315014;](https://doi.org/10.1101/2024.10.09.24315014) this version posted October 9, 2024. The copyright holder for this
preprint <mark>(which was not certified by peer review)</mark> is the author/funder, who has grant

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.09.24315014;](https://doi.org/10.1101/2024.10.09.24315014) this version posted October 9, 2024. The copyright holder for this
preprint <mark>(which was not certified by peer review)</mark> is the author/funder, who has grant

| Name | Concentration/units | Commercial source | Comments |
|---|---------------------|--|---|
| PCR Tube Strip with Attached Flat Caps | NA | ThermoFisher, Cat: AB2000 | NA |
| 1.5 ml DNA LoBind tubes | NA | Eppendorf, Cat: 0030108051-250EA | Use LoBind tubes |
| 2 ml round bottom tubes | NA | Starlab, Cat: S1620- 2700-C or Eppendorf, Cat: 0030120094 | Avoid using LoBind tubes |
| Pipettes and pipette tips P2, P10, P20, P100, P200, P1000, Multichannel | NA | Any | NA |
| Centrifuge /Microplate centrifuge | NA | Any | NA |
| Vortex mixer | NA | Any | NA |
| Thermal cycler | NA | Any | NA |
| Heating block for 1.5/2 mL tubes | NA | Any | NA |
| Sequencing device | NА | Flongle, MinION Mk1B, GridION | NА |
| Device for live basecalling | NA | GridION or A powerful laptop | A laptop with minimum 8 Gb GPU (RTX 3060 or higher), 16 GB Ram, 1 Tb M.2 NVMe SSD |

902 Disclaimer: Some parts of the following protocol has been copied directly from the

903 manufacturer's official website or from the kit manual. Therefore, all the proprietary

904 information mentioned below remains the sole property of the kits manufacturer.

Before sample preparation

- 907 It is important to divide all reagents into smaller aliquots to avoid multiple freeze-thaw cycles and reduce the likelihood of cross-contamination.
- Warm up 0.05% trypsin EDTA at 37°C. Prepare 1x DNase I buffer and store in the fridge
- before use. Make a fresh batch of REPLI-g Master Mix following manufacturer's instructions.
- Take out aliquots of Buffer D2, Stop Solution, and any other reagents from the freezer, and
- store in the refrigerator or on ice until needed. Thaw all the reagents at room temperature or
- on ice as per manufacturers recommendation.
- This protocol can be used on BD BACTEC (Becton, Dickinson and Company, NJ, USA) or any
- blood culture (FPBC) samples flagged positive with an automated culture system. Protocol M-
- 916 15 mNGS can also be applied to rapid culture enriched blood samples (REBC; for example, 1-
- 10 mL patient blood samples incubated for 8 hours in BD BACTEC media bottles), once the
- 918 enriched sampled have at least 10^3 CFU/mL bacterial concentration. FPBC samples can be
- used directly for CHDD; however, REBC samples need to be pre-processed to concentrate the
- sample before continuing with this protocol. It is crucial to use fresh samples for CHDD, as
- frozen or improperly stored samples can lead to the lysis of bacterial cells. This may lead to a considerable loss of bacterial DNA during CHDD.

Pre-processing REBC samples

- Transfer 1.5 mL REBC samples aseptically to a 2 mL round bottom microcentrifuge tube and
- spin at 8,000xg for 5 minutes. Slowly aspirate the supernatant without disturbing the pellet
- and gently resuspend the pellet in 800 μL 2.25% saponin. Proceed to the step 2 of CHDD
- protocol below.
- 928 Note* It is important to use round/wide bottom 2 mL microcentrifuge tubes to minimize bacterial cell loss while 929 aspirating the supernatant during the initial washing steps.
-

933 Host depletion

- 934 1. Add 400 μL FPBC sample to 400 μL 4.5% saponin (final saponin concentration will be 2.25%
- 935 after mixing) in a 2 mL wide bottom sterile microcentrifuge tube and gently pipette mix for at 936 least 4 to 5 times.
- 937 2. Add 1 µL DNase I (300 units/ μ L) to the REBC/FPBC sample, pulse vortex at low speed for 5
- 938 seconds and incubate the sample at 25°C in a heating block for 10 minutes at 800 rpm.
- 939 Note* Adding DNase I decreases the viscosity of the sample by degrading a substantial amount of DNA
- 940 (desirably from the host) after selective host cell lysis. The DNA released from the host cells can be extremely
- 941 sticky, and often adhere to pipette tips or microfuge tubes. As a result, there's a risk of losing desired/targeted
- 942 bacterial cells because they might adhere to the sticky host DNA and get affixed to the pipette tips and/or
- 943 microcentrifuge tube.
- 944 3. Perform a quick spin and add 800 μL molecular grade water to the sample. Pipette mix 4 to 945 5 times and incubate for 1 minute at room temperature.
- 946 4. Add 44 μL 5 M molecular grade NaCl (final concentration is 137 mM; same as PBS) to the
- 947 sample, invert the tubes 3 to 4 times to mix and centrifuge at 10,000x g for 5 minutes.
- 948 5. Carefully remove the supernatant without touching or disturbing the pellet and resuspend
- 949 in 1 mL molecular grade 1x Dulbecco's Phosphate Buffered Saline (DPBS, Without calcium,
- 950 magnesium, or phenol).
- 951 6. Centrifuge the sample at 10,000x g for 3 minutes and carefully remove the supernatant 952 without touching or disturbing the pellet.
- 953 7. Resuspend the pellet in 398 μL 1x DNase I buffer, add 2 μL DNase I (300 units/ μ L) to the
- 954 sample and incubate at 37°C with shaking at 800 RPM for 15 minutes.
- 955 8. Following incubation, add 1 mL 0.05% trypsin EDTA directly to the sample, pipette mix at
- 956 least 8 to 10 times and incubate at room temperature for 1 minute.
- 957 Note* Some bacterial cells may form aggregates in the sample, so adding 0.05% trypsin EDTA can separate the
- 958 cells and ensure an even distribution for subsequent procedures. The trypsinisation step does not affect
- 959 bacterial viability and/or cell wall integrity.
- 960 9. Repeat step 6 and resuspend the pellet in 1 mL 1x DPBS.

- 961 Note* This is the end of host depletion with M-15. After this, 4 μ L of host depleted bacterial cell material in
- 962 DPBS from step 9 can be used directly for alkaline lysis and whole genome amplification (WGA; protocol 1) using
- 963 the REPLI-g Single Cell Kit.

964 DNA extraction and Whole Genome Amplification

965 10. Prepare sufficient Buffer D2 in a PCR tube for the total number of 12 reactions.

966 Note* Buffer D2 should not be stored longer than 2 months at-20 °C.

967 11. Place 4 μ L cell material into a PCR tube containing 3 μ L buffer D2. Mix by flicking the tube

- 968 and centrifuge briefly.
- 969 12. Incubate at 65°C for 10 min with heated lid on and then add 3 µL Stop Solution. Mix by

970 flicking the tube and centrifuge briefly. Prepare a master mix according to the instruction

971 below.

- 972 Note* Avoid using H_2O for preparing the master mix.
- 973 13. For each reaction, add 5 µL DNA from step 12 and incubate at 30°C for 1 hour with 974 heated lid off.
- 975 14. Inactivate REPLI-g sc DNA Polymerase by heating the sample for 3 min at 65°C with
- 976 heated lid on.
- 977 Note* After this step amplified host depleted DNA can be diluted 5-fold in molecular grade H₂O, measured with
- 978 Qubit Br assay and used directly for debranching and subsequently sequencing library preparation.

979 Debranching and bead cleanup

980 15. In a clean 0.2 mL PCR tube, mix the reagents for debranching in the following order.

- 982 16. Mix the reagents by flicking the tube and centrifuge briefly. Incubate the reaction for 10 983 minutes at 37°C.
- 984 17. Resuspend the DNA binding beads (e.g., AMPure XP or Aline biosciences) by vortexing.
- 985 18. Add 15 μ L of the bead suspension (0.5x) to the DNA sample and mix by pipetting.
- 986 19. Incubate for 5 minutes at room temperature.
- 987 20. Spin down and pellet the sample on a magnetic rack/plate until supernatant is clear and
- 988 colourless. Keep the tube on the magnet, and pipette off the supernatant.
- 989 21. Keeping the tube on the magnet, wash the beads with 200 μ L of freshly prepared 70%
- 990 ethanol without touching/disturbing the pellet. Remove the ethanol carefully using a
- 991 pipette and discard.
- 992 22. Repeat the previous ethanol washing step.
- 993 23. Spin down and put the tube back on the magnetic rack/plate. Pipette off any residual
- 994 ethanol. Open the lid and allow the tubes to dry for ~30 seconds, but do not dry the 995 pellet to the point of cracking.
- 996 24. Remove the tube from the magnetic rack/plate and resuspend the pellet in 15 µL 997 nuclease-free water. Incubate for 2 min at room temperature.
- 998 25. Pellet the beads on a magnet until the eluate is clear and colourless.
- 999 26. Remove and retain 12 µL of eluate into a clean 0.2 mL PCR tube.
- 1000 Note* This is the end of debranching and DNA cleanup. After this step, cleaned and debranched DNA products
- 1001 can be used for library preparation with Rapid Barcoding (rapid but low yield) or Ligation sequencing kit (highest 1002 yield).

1004 Rapid barcoding (low-medium yield protocol)

1005 Barcoding

1006 1. Combine the following components per PCR tube:

- 1008 2. Mix the reagents by flicking the tube and spin briefly.
- 1009 3. Incubate the samples at 30°C in a thermal cycler for 1 minute and 80°C for 1 minutes with 1010 heated lid off.
- 1011 4. Spin and pool all the rapid barcoded DNA in 1.5 mL Eppendorf DNA LoBind tube to make 1012 1,200 ng in a volume of 50 µL. Example, for 6 samples, take 200 ng $(200 \times 6 = 1,200 \text{ ng})$ 1013 DNA per sample.
- 1014 5. Resuspend the DNA binding beads (e.g., AMPure XP or Aline biosciences) by vortexing.
- 1015 6. Add 25 µL (0.5x) of resuspended beads to the sample and mix by flicking the tube multiple 1016 times.
- 1017 7. Incubate the tube for 5 minutes at room temperature.
- 1018 8. Spin down the sample and pellet on a magnetic rack/plate until the supernatant is clear 1019 and colourless. Keep the tube on the magnet, and carefully pipette off the supernatant.
- 1020 9. Wash the beads with 250 μl long Fragment Buffer (LFB) without touching/disturbing the 1021 pellet. Remove LFB carefully using a pipette and discard.
- 1022 Note* Flick the beads to resuspend, spin and put back on magnet and remove supernatant using a pipette. Long 1023 Fragment Buffer Expansion (EXP-LFB001) can be purchased separately from ONT.
- 1024 10. Repeat the previous LFB washing step.

- 1025 11. Spin down and place the tube back on the magnet. Pipette off any residual supernatant.
- 1026 Allow to dry for ~30 seconds, but do not dry the pellet to the point of cracking.
- 1027 12. Remove the tube from the magnetic rack/plate and resuspend the pellet in 22 μ L Elution
- 1028 Buffer (EB). Spin down briefly and incubate for 2 minutes at room temperature.
- 1029 13. Pellet the beads on a magnetic rack/plate until the eluate is clear and colourless, for at 1030 least 1 minute.
- 1031 14. Remove and retain 20 µL of eluate containing the DNA library into a clean 1.5 mL 1032 Eppendorf DNA LoBind tube.
- 1033 Rapid adapter ligation and loading
- 1034 15. Quantify 1 µL rapid barcoded and cleaned DNA using a Qubit fluorometer.
- 1035 16. Add 1 µL rapid adaptor (RAP) to 10 µL of barcoded DNA in EB in a PCR tube, flick multiple
- 1036 times to mix, spin briefly and incubate for 10 minutes at 20°C with the heated lid off.
- 1037 17. Load 100 ng (51.36 fmol; considering 3kb product size) of final prepared library onto a 1038 flow cell following manufacturers recommendation.
- 1039
- 1040
- 1041
- 1042
- 1043
- 1044
- 1045
- 1046
- 1047
-
- 1048
- 1049

It is made available under a CC-BY-NC-ND 4.0 International license.

1050 Ligation sequencing (high yield protocol)

1051 End prep

1052 1. Combine the following components per PCR tube:

1053

- 1054 2. Mix gently by flicking the tube, and spin down.
- 1055 3. Using a thermal cycler, incubate at 20°C for 5 minutes with heated lid off.
- 1056 4. Incubate at 65°C for 5 minutes with heated lid on.

1057 Native barcode ligation and cleanup

1058 5. Combine the following components per PCR tube:

- 1060 6. Mix gently by flicking the tube, and spin down.
- 1061 7. Incubate the reaction for 10 minutes at 20° C with heated lid off.
- 1062 8. Resuspend the AMPure XP beads by vortexing.
- 1063 9. Add 13.25 μ L of resuspended AMPure XP beads to the reaction and mix by pipetting.
- 1064 10. Incubate for 5 minutes at room temperature.
- 1065 11. Spin down the sample and pellet on a magnet until supernatant is clear and colourless. Keep the 1066 tube on the magnet, and pipette off the supernatant.
- 1067 12. Keep the tube on the magnet and wash the beads with 200 µL of freshly prepared 70% ethanol
- 1068 without disturbing the pellet. Remove the ethanol using a pipette and discard.

- 1069 13. Repeat the previous step.
- 1070 14. Spin down and place the tube back on the magnet. Pipette off any residual supernatant. Allow to
- 1071 dry for \approx 30 seconds, but do not dry the pellet to the point of cracking.
- 1072 15. Remove the tube from the magnetic plate and resuspend pellet in 15 μ L nuclease-free water.
- 1073 Incubate for 2 min at room temperature.
- 1074 16. Pellet the beads on a magnet until the eluate is clear and colourless.
- 1075 17. Remove and retain 12 uL of eluate into a clean PCR tube.
- 1076 Measure DNA concentration with Qubit and pool all the barcoded DNA in 1.5 mL Eppendorf DNA
- 1077 LoBind tube to make 350 ng in a volume of 30 µL H2O. Example, for 6 samples, take 58.33 ng (58.33 x
- 1078 6 = 350 ng) DNA per sample.

1079 **Adapter ligation and cleanup and loading**

1080 18. Combine the following components:

- 1082 19. Ensure the components are thoroughly mixed by pipetting, and spin down.
- 1083 20. Incubate the reaction for 15 minutes at 20°C.
- 1084 21. Resuspend the AMPure XP beads by vortexing.
- 1085 22. Add 25 μ L (0.5x) of resuspended AMPure XP beads to the reaction and mix by pipetting.
- 1086 23. Incubate for 5 minutes at room temperature.
- 1087 24. Spin down the sample and pellet on a magnet until supernatant is clear and colourless. Keep the 1088 tube on the magnet, and pipette off the supernatant.
- 1089 25. Wash the beads by adding 250 μl long Fragment Buffer (LFB).
- 1090 Note* Do not flick the beads to resuspend. Just gently wash and remove the supernatant using a
- 1091 pipette and discard.
- 1092 26. Repeat the previous step.
- 1093 27. Spin down and place the tube back on the magnet. Pipette off any residual supernatant. Allow to 1094 dry for ~30 seconds, but do not dry the pellet to the point of cracking.
- 1095 28. Remove the tube from the magnetic rack and resuspend the pellet in 17 μ L Elution Buffer (EB).
- 1096 Spin down and incubate for 2 minutes at room temperature.

- 1097 29. Pellet the beads on a magnet until the eluate is clear and colourless, for at least 1 minute.
- 1098 30. Remove and retain 15 µL of eluate containing the DNA library into a clean 1.5 mL Eppendorf DNA 1099 LoBind tube.
- 1100 $31.$ Quantify 1 μ L of adapter ligated and barcoded DNA using a Qubit fluorometer.
- 1101 32. Load 100 ng (51.36 fmol; considering 3kb) of final prepared library onto a flow cell following
- 1102 manufacturers recommendation.
- 1103 Note* The typical library size after this stage is around 3 kb. However, users can verify this by running the library
- 1104 on a gel or TapeStation for a few batches. Once the average expected library size is determined (sample or site-
- 1105 wise), there will be no need to repeat this for every batch of samples.
- 1106 For loading sequencing library or washing flow cells, follow the manufacturers recommended
- 1107 protocols.